Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.50 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.50 |
| ▸ | TOP2A | P11388 | 4/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580654 | 1.00 | TK1 (0.50) | TK1RNASE1TOP2ADHFR | |
| SCHEMBL24233273 | 0.92 | TK1 (0.50) | TK1RNASE1TOP2ADHFR | |
| SCHEMBL22020924 | 0.92 | TK1 (0.50) | TK1RNASE1TOP2ADHFR | |
| SCHEMBL24059205 | 0.92 | TK1 (0.50) | TK1RNASE1TOP2ADHFR | |
| SCHEMBL22314627 | 0.90 | TK1 (0.51) | TK1RNASE1TOP2ADHFR | |
| SCHEMBL25373343 | 0.89 | LMNA (0.47) | TK1RNASE1TOP2A | |
| SCHEMBL22020929 | 0.87 | TK1 (0.46) | TK1RNASE1TOP2ADHFR | |
| SCHEMBL22021510 | 0.87 | TK1 (0.46) | TK1RNASE1TOP2ADHFR | |
| SCHEMBL25757662 | 0.87 | RNASE1 (0.51) | TK1RNASE1TOP2A | |
| SCHEMBL22020923 | 0.86 | TK1 (0.48) | TK1RNASE1TOP2ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-04-28 | — | — | US | disclosed |
| WO-2021234459-A9 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022004388-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | 国立大学法人大阪大学 | 2022-01-06 | — | — | WO | disclosed |
| EP-3919501-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | Osaka University (JP) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021234459-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | PFIZER INC. | 2021-07-01 | — | — | US | disclosed |
| US-5618704-A | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling | ISIS PHARMACUETICALS, INC. (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0649429-A4 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES. | ISIS PHARMACEUTICALS INC (US) | 1996-04-10 | — | — | EP | disclosed |
| US-5489677-A | NUCLEASE RESISTANT OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0649429-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5386023-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1994022893-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022894-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND PREPARATION THEREOF THROUGH RADICAL COUPLING | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022883-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDES AND THEIR PREPARATION | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022454-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT OXYGEN AND NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994000467-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | TK1 166/4885RNASE1 95/4885TOP2A 183/4885 |
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, NSUN3 | TK1 1053/4885RNASE1 1/4885TOP2A 3131/4885 |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | NT5C3B, DUT, RNGTT | TK1 99/4885RNASE1 84/4885TOP2A 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.